note 17 2014 sales-type leases and financing receivables in april 2017 , in conjunction with the implementation of a new 201cgo-to-market 201d business model for the company's u.s .
dispensing business within the medication management solutions ( 201cmms 201d ) unit of the medical segment , the company amended the terms of certain customer leases for dispensing equipment within the mms unit .
the modification provided customers the ability to reduce its dispensing asset base via a return provision , resulting in a more flexible lease term .
prior to the modification , these leases were accounted for as sales-type leases in accordance with accounting standards codification topic 840 , "leases" , as the non- cancellable lease term of 5 years exceeded 75% ( 75 % ) of the equipment 2019s estimated useful life and the present value of the minimum lease payments exceeded 90% ( 90 % ) of the equipment 2019s fair value .
as a result of the lease modification , the company was required to reassess the classification of the leases due to the amended lease term .
accordingly , most amended lease contracts were classified as operating leases beginning in april 2017 .
the change in lease classification resulted in a pre-tax charge to earnings in fiscal year 2017 of $ 748 million , which was recorded in other operating expense , net .
beginning april 1 , 2017 , revenue associated with these modified contracts has been recognized on a straight-line basis over the remaining lease term , along with depreciation on the reinstated leased assets .
the company's consolidated financial results in 2018 and 2017 were not materially impacted by the financing receivables remaining subsequent to the lease modification discussed above .
note 18 2014 supplemental financial information other income ( expense ) , net .

(Millions of dollars)
2018
2017
2016
Losses on debt extinguishment (a)
$(16)
$(73)
$—
Vyaire Medical-related amounts (b)
288
(3)
—
Other equity investment income
8
3
8
Losses on undesignated foreign exchange derivatives, net
(14)
(11)
(3)
Royalty income (c)
51
—
—
Gains on previously held investments (d)
—
24
—
Other
—
3
7
Other income (expense), net
$318
$(57)
$11

( a ) represents losses recognized upon our repurchase and extinguishment of certain senior notes , as further discussed in note 15 .
( b ) represents amounts related to the company 2019s 2017 divestiture of a controlling interest in its former respiratory solutions business and the subsequent sale in 2018 of the remaining ownership interest .
the amount in 2018 includes the gain on the sale of the remaining non-controlling interest and transition services agreement income , net of the company's share of equity investee results .
the amount in 2017 represents the company 2019s share of equity investee results , net of transition services agreement income .
additional disclosures regarding these divestiture transactions are provided in note 10 in the notes to consolidated financial statements .
( c ) represents the royalty income stream acquired in the bard transaction , net of non-cash purchase accounting amortization .
the royalty income stream was previously reported by bard as revenues .
( d ) represents an acquisition-date accounting gain related to a previously-held equity method investment in an entity the company acquired. .

Question: Analyse this data from a financial earnings document. what is the average of total other income from 2016-2018 , in millions?
Choices:
261
38.85714
90.66667
1.35323
33.66667
Correct choice index: 2